Author: Newsdesk

CUMMING, Ga., March 27, 2026 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL), the nation’s leading builder of luxury homes, today announced the final opportunity to purchase a new home at CrossCreek by Toll Brothers, an exclusive community located off exit 13 on Georgia State Route 400 in Cumming, Georgia. With only one luxury home remaining, this is the last chance for home shoppers to become part of this serene and highly sought-after neighborhood of estate-sized homes nestled along a quiet creek.

The final home available at CrossCreek by Toll Brothers is priced at $1,372,000 and features five bedrooms with 3,545 square feet of elegant living space, a first-floor bedroom suite ideal for visiting guests, a well-designed kitchen with an oversized walk-in pantry, and a two-story great room that flows seamlessly to the outdoor living space. The community is conveniently located near outdoor recreation, boutique shopping, and dining, and is served by the highly rated Forsyth County School District, including South Forsyth High School.

“CrossCreek by Toll Brothers is an exceptional community offering the very best of luxury living in a tranquil setting,” said Eric White, Georgia Division President of Toll Brothers in Georgia. “We are thrilled to offer this final opportunity for home shoppers to call this community home.”

The offsite Sales Center is open by appointment only and located at 2010 Rosewood Drive in Alpharetta. For more information about the final home remaining at CrossCreek by Toll Brothers, and other new home communities throughout the Atlanta area, contact Toll Brothers at 888-686-5542 or visit TollBrothers.com/GA.

About Toll Brothers

Toll Brothers, Inc., a Fortune 500 Company, is the nation’s leading builder of luxury homes. The Company was founded in 1967 and became a public company in 1986 with common stock listed on the New York Stock Exchange under the symbol “TOL.” Toll Brothers builds new homes and communities in over 60 markets across the United States, serving first-time, move-up, active-adult, and second-home buyers. The Company also operates its own architectural, engineering, mortgage, title, land development, smart home technology, landscape, and building components manufacturing businesses.

Toll Brothers was named the #1 Most Admired Home Builder in Fortune magazine’s 2026 list of the World’s Most Admired Companies®, the ninth year the Company has achieved this honor. Toll Brothers has also been named Builder of the Year by Builder magazine and is the first two-time recipient of Builder of the Year from Professional Builder magazine. For more information visit TollBrothers.com.

From Fortune, ©2026 Fortune Media IP Limited. All rights reserved. Used under license.

Contact: Andrea Meck | Toll Brothers, Senior Director, Public Relations & Social Media | 215-938-8169 | [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/410c79ce-8771-4e56-be21-40e62e29e204

Sent by Toll Brothers via Regional Globe Newswire (TOLL-REG)

Dubai and New York, March 27, 2026 — VEON Ltd. (Nasdaq: VEON; “VEON” or the “Company”), a global digital operator, today provided an update underscoring the strong alignment between its management and shareholders, reflected in meaningful share ownership and disciplined capital allocation.

As of the date of this release, members of VEON’s management collectively hold 1.84% of the Company’s total share capital in the form of American Depositary Shares (ADSs). This level of ownership reflects a clear and tangible alignment with shareholder interests and reinforces management’s commitment to long-term value creation. As part of its commitment to transparency and governance, VEON discloses that its Chief Executive Officer, Kaan Terzioglu, now holds slightly more than 1% of the Company’s total share capital, exceeding the relevant disclosure threshold for insider ownership as was reported earlier in the Company’s 2025 Form 20-F.

VEON’s capital allocation framework also reflects the commitment to shareholder value creation. The Company is progressing with its previously announced USD 100 million buyback program of VEON ADSs and/or outstanding bonds, commenced on November 14, 2025. As of March 26, 2026, VEON has repurchased 745,420 ADSs for a total consideration of USD 39.0 million and USD 3 million of the 2027 Notes. Including the earlier buybacks first announced in August 2024, VEON has repurchased a total of 2.89 million ADSs for an aggregate consideration of USD 139.0 million. 

In addition, VEON recently introduced a capital allocation policy targeting the return of at least USD 100 million to shareholders annually through share buybacks, further reinforcing its commitment to delivering consistent and measurable shareholder returns.

“VEON’s strategy is firmly anchored in delivering long-term value for shareholders. The alignment between management ownership and our capital allocation policy reflects our confidence in the Company’s direction and our focus on sustainable growth,” said Kaan Terzioglu, Chief Executive Officer of VEON.

This alignment is further supported by VEON’s continued execution of its digital operator strategy, serving over 150 million connectivity customers and more than 205 million quarterly digital users across five frontier markets. The Company remains focused on driving sustainable growth across its consumer and enterprise service lines, with a disciplined approach to capital deployment.

Through a combination of aligned incentives, disciplined capital returns, and continued execution of its digital operator strategy, VEON generates value for its shareholders while supporting the growth ambitions of its customers, markets, and partners.

About VEON  
VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity and more than 205 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

Forward-Looking Statements Disclaimer

This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to VEON’s strategic ambitions and the share ownership of its management team. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to VEON’s strategic ambitions and the share ownership of its management team, among others discussed in the section entitled “Risk Factors” in VEON’s 2025 Form 20-F filed with the SEC on March 16, 2026 and other public filings made by VEON with the SEC. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

Contact Information 

VEON Communications
[email protected]

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Driven Brands Holdings Inc. (“Driven Brands” or the “Company”) (NASDAQ: DRVN) for violations of the federal securities laws on behalf of investors who purchased or acquired Driven Brands securities between May 9, 2023, and February 24, 2026, inclusive (the “Class Period”).

On March 9, 2026, a complaint was filed against the Company and certain of its current and former officers, alleging that throughout the Class Period, Defendants misrepresented and failed to disclose that Driven Brands had identified at least ten categories of errors in its financial statements, including errors related to: (1) the recording of leases affecting the right of use assets and right of use liabilities recorded in the Company’s consolidated balance sheet; (2) opening and ending cash balances and operating cash flows, leading to overstatements of cash and revenue and understatement of selling, general, and administrative expenses in Driven Brands’ consolidated statements of operations; (3) presentation of supply and other expenses as company-operated store expenses; (4) income tax provision; (5) supply and other revenue; (6) fixed assets; (7) cloud computing; (8) lease cash applications; (9) balance sheet and income statement misclassifications; and (10) improperly recognized revenue in Driven Brands’ Automotive Training Institute business.

When investors learned the truth, Driven Brands’ common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Driven Brands’ common stock, and wish to participate, or learn more about your eligibility, please contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

Any investor who wishes to serve as Lead Plaintiff must act before May 8, 2026.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected]

SOURCE: Lowey Dannenberg P.C.

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Navan, Inc. (“Navan” or the “Company”) (NASDAQ: NAVN) for violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Navan common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s October 2025 initial public offering (“IPO” or the “Offering”).

On February 23, 2026, a complaint was filed against the Company, certain of its officers, directors, and underwriters in connection with the IPO, alleging that the Offering Documents were false and misleading and omitted to state that the Company would increase its sales and marketing expenses by 39% just months after the IPO to sustain its revenue, Gross Booking Volume, and usage yield growth.

As a result, Navan’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Navan’s common stock in connection to the IPO, and wish to participate, or learn more, please contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

Any investor who wishes to serve as Lead Plaintiff must act before April 24, 2026.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected] 

SOURCE: Lowey Dannenberg P.C.

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Paysafe Limited (“Paysafe” or the “Company”) (NYSE: PSFE) for violations of the federal securities laws on behalf of investors who purchased or acquired Paysafe securities between March 4, 2025 and November 12, 2025, inclusive (the “Class Period”).

On October 16, 2025, a complaint was filed against the Company and certain of its current officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Paysafe’s ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company’s credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on the Company’s revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

When investors learned the truth, Paysafe’s common stock declined precipitously, injuring investors.

If you suffered a loss of more than $100,000 in Paysafe’s common stock, and wish to participate, or learn more about your eligibility, please contact our attorneys Andrea Farah ([email protected]) at (914)733-7256 or Vincent R. Cappucci Jr. ([email protected]) at (914)733-7278.

Any investor who wishes to serve as Lead Plaintiff must act before April 7, 2026.

About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.

Contact:

Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: [email protected] 

SOURCE: Lowey Dannenberg P.C.

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments.

“2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease,” said Chandler Robinson, MD, Chief Executive Officer of Monopar. “We also recently strengthened our leadership team with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer as we prepare for the potential launch of ALXN1840. We are grateful to the Wilson disease patients and their families whose experiences have informed our efforts to advance ALXN1840.”

Recent Program Developments

ALXN1840 – NDA Submission Planned for Mid-2026 for Wilson Disease

Wilson disease is a rare genetic disorder characterized by impaired copper elimination, resulting in toxic accumulation in organs such as the liver and brain. ALXN1840 binds and mobilizes copper and has a novel mechanism of action as an albumin tripartite complex (“ATC”) activator that differentiates it from currently available first-line therapies.

Based on recent interactions with the U.S. Food and Drug Administration (“FDA”), Monopar plans to submit a New Drug Application (“NDA”) for ALXN1840 in mid-2026.

ALXN1840 updates:

• EASL 2025: Presented pooled long-term efficacy and safety data (n=255; median treatment duration 2.63 years), with additional safety data (n=266) supporting a favorable safety profile, as a late-breaking abstract
• ANA 2025: Presented data demonstrating long-term neurological benefit; the abstract was selected for oral and poster presentation and designated an “Abstract of Distinction”
• Journal of Hepatology / AASLD 2025: Reported statistically significant improvement in copper balance, with sustained improvement in daily copper balance driven by increased fecal copper excretion
• EL-PFDD: Attended externally led patient-focused drug development (“EL-PFDD”) meeting with the FDA on January 29, 2026. During the meeting, patients and caregivers described the burden of Wilson disease, shared their experience with the currently available treatments, and highlighted the urgent need for additional treatment options
• Upcoming 2026 presentations: Abstracts accepted for presentation at EASL 2026 and the American Academy of Neurology (“AAN”) 2026 Annual Meeting, including:
  • Tiomolybdate choline stabilizes liver disease and improves neurological symptoms as well as quality of life in treatment-experienced Wilson disease patients (EASL 2026 oral presentation)
  • Greater clinical benefit with tiomolybdate choline versus standard-of-care in neurologic Wilson disease patients in the Phase 3 FoCus Trial (AAN 2026 late-breaking oral and poster presentation)

MNPR-101 Radiopharmaceutical Programs

MNPR-101-Zr (zirconium-89), MNPR-101-Lu (lutetium-177), and MNPR-101-Ac (actinium-225) target the urokinase plasminogen activator receptor (“uPAR”), which is expressed in multiple aggressive cancers, including triple-negative breast, colorectal, and pancreatic cancers.

MNPR-101 platform update:

• Ongoing Phase 1 clinical activity in Australia for MNPR-101-Zr and MNPR-101-Lu
• Investigational new drug (“IND”) clearance received for MNPR-101-Lu to initiate a Phase 1 clinical trial in the US
• FDA-authorized physician-sponsored Expanded Access Program at Excel Diagnostics and Nuclear Oncology Center (“EDNOC”) in Houston, Texas
• Preclinical development of MNPR-101-Ac

Financings

In 2025, Monopar strengthened its balance sheet through the following financing activities:

• Completed an underwritten public offering generating approximately $91.9 million, after a concurrent repurchase of common stock but before offering expenses

Results for the Fourth Quarter and Year Ended December 31, 2025, Compared to the Fourth Quarter and Year Ended December 31, 2024

Cash and Net Loss

Cash, cash equivalents and short-term investments as of December 31, 2025, were $140.4 million.

Monopar expects its current funds to support operations through at least December 31, 2027, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development.

Net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share, compared to $10.9 million, or $2.23 per share, for the fourth quarter of 2024.

Net loss for the year ended December 31, 2025, was $13.7 million, or $1.85 per share, compared to $15.6 million, or $4.11 per share, for the year ended December 31, 2024.

Research and Development (“R&D”) Expenses

R&D expenses for the fourth quarter of 2025 were $3.9 million compared to $9.9 million for the fourth quarter of 2024. The decrease was primarily due to the absence of one-time expenses incurred in connection with the in-licensing of ALXN1840 in 2024, partially offset by higher R&D personnel expenses (driven by increased headcount and compensation), increased clinical material and manufacturing costs for the ALXN1840 program, and higher other R&D expenses.

R&D expenses for the year ended December 31, 2025, were $9.9 million compared to $13.0 million for the year ended December 31, 2024. The decrease was primarily due to the absence of one-time expenses incurred in connection with the in-licensing of ALXN1840 in 2024, as well as lower radiopharmaceutical clinical trial costs reflecting a shift in focus following the in-licensing, partially offset by higher R&D personnel expenses (driven by increased headcount and compensation), increased clinical material and manufacturing costs for the ALXN1840 program, and higher other R&D expenses.

General and Administrative (“G&A”) Expenses

G&A expenses for the fourth quarter of 2025 were $2.2 million compared to $1.2 million for the fourth quarter of 2024. The increase was primarily due to higher Board of Directors (the “Board”) and G&A personnel expenses (including stock-based compensation and bonuses), higher patent legal fees, and other increases in G&A expenses.

G&A expenses for the year ended December 31, 2025, were $6.8 million compared to $3.2 million for the year ended December 31, 2024. The increase was primarily due to higher Board and G&A personnel expenses (including stock-based compensation and bonuses), higher patent legal fees, and other increases in G&A expenses.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage ALXN1840 for Wilson disease, and radiopharmaceutical programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers. For more information, including links to SEC filings containing detailed financial information, please visit: Annual Reports :: Monopar Therapeutics Inc. (MNPR).

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: that Monopar is making continued progress toward a planned New Drug Application (“NDA”) submission for ALXN1840 in Wilson disease; that Monopar is preparing for the potential launch of ALXN1840; that Monopar plans to submit an NDA for ALXN1840 to the FDA in mid-2026; and that Monopar expects its current funds to support operations through at least December 31, 2027. The forward-looking statements involve risks and uncertainties including, but not limited to: uncertainties related to the regulatory process that Monopar intends to initiate related to ALXN1840, including the submission of the NDA to the FDA, and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which Monopar receives marketing approval, and Monopar’s ability to competitively market any such products as compared to larger pharmaceutical firms; Monopar’s ability to raise sufficient funds in order for the Company to support continued preclinical, clinical, regulatory, precommercial and commercial development of its programs and to make contractual milestone payments, as well as its ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc.
Investor Relations
Quan Vu
Chief Financial Officer
[email protected]

Follow Monopar on social media for updates: 

X: @MonoparTx  LinkedIn: Monopar Therapeutics

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — Cambridge Acquisition Corp. (Nasdaq: CAQUU) (the “Company”) announced today that, commencing March 30, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols “CAQ” and “CAQUW,” respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol “CAQUU.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cambridge Acquisition Corp.

Cambridge Acquisition Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to us or our management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact
 
Brent Michael Cox
One Liberty Square, 13th FL
Boston, MA 02109
Telephone: (617) 396-4911

NEW YORK, March 27, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the presentation of new data further evaluating the effects of LB-102 on cognitive performance in the Phase 2 NOVA-1 clinical trial in patients with acute schizophrenia. LB-102, a novel, once-daily, oral investigational small molecule, is a selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. The post hoc analysis was designed to assess whether the improvement in cognitive performance, as measured by the Global Cognition composite score, was a direct effect of LB-102 or an indirect consequence of the effect of LB-102 on total schizophrenia symptoms. Results of the analysis demonstrated that the cognitive benefit was primarily, and statistically significantly, a direct effect of LB‑102. The presentation, titled “LB-102 for Cognition in Patients with Schizophrenia: An Exploratory Post Hoc Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2 Study” was highlighted at the Schizophrenia International Research Society (SIRS) meeting on March 27^th in Florence, Italy.

“There remains significant unmet need for new schizophrenia therapies that offer patients the potential for improvements in cognitive symptoms that drive functional impairment,” said Anna Eramo, M.D., Chief Medical Officer of LB Pharmaceuticals. “This new analysis provides additional insights into the potential of LB-102 to offer differentiated improvement in cognitive performance that is independent of its effect on overall schizophrenia symptoms. Based on these robust data, we are prospectively evaluating cognitive performance as a secondary endpoint in our recently initiated pivotal Phase 3 trial (NOVA-2) of LB-102 in patients with acute schizophrenia, our planned open label extension trial in patients with schizophrenia, as well as our ongoing and planned trials in bipolar 1 depression and adjunctive MDD.”

In addition, an encore oral presentation titled “LB-102 for Acute Schizophrenia in Adults: Results from the Phase 2 NOVA-1 Clinical Trial, with a Focus on PANSS Marder Factor Scores” was also presented at SIRS. This presentation reviewed an analysis exploring LB-102’s effect on PANSS Marder factor, which provides a more nuanced framework for understanding the complexities of schizophrenia symptoms. This analysis evaluated LB‑102’s effects across the five PANSS Marder factors: Positive Symptoms, Negative Symptoms, Disorganized Thought, Hostility/Excitability, and Anxiety/Depression.

In the Phase 2 NOVA-1 trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial. LB-102 was generally safe and well tolerated, exhibiting a potentially class-leading safety profile with low rates of extrapyramidal symptoms (EPS) (including akathisia), minimal sedation and few gastrointestinal (GI) side effects alongside effects on negative symptoms and cognitive performance. A dose dependent, and statistically significant improvement in the global cognition composite score was observed at all dose levels in a patient population that was not enriched for severe cognitive impairment at baseline.

In addition to the oral and poster presentation, the Company sponsored a Satellite Symposium titled “Next-Generation Perspectives in Schizophrenia: Translating Emerging Science Into Practice” featuring John Kane, M.D., Professor, Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine and Christoph Correll, M.D., Professor of Child and Adolescent Psychiatry at the Charité-Universitätsmedizin Berlin and Donald and Barbara Zucker School of Medicine.

The poster and oral presentations are available on the LB Pharma Publication page on LB Pharmaceuticals website at https://lbpharma.us/.

About LB-102

LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the U.S., LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT–7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. A Phase 3 clinical trial (NOVA-2) of LB-102 for schizophrenia and a Phase 2 clinical trial (ILLUMINATE-1) of LB-102 for bipolar depression have been initiated, and a Phase 2 trial in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases. 

About LB Pharmaceuticals

LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the therapeutic benefits of LB-102; and the design, objectives, initiation, timing, progress and results of current and future clinical trials of LB-102, including the Phase 2 NOVA-1 trial and the Phase 3 NOVA-2 trial. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact: 
Ellen Rose
[email protected]